Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Tae-Ok KimIn Jae OhBo Gun KhoHa Young ParkJin Sun ChangCheol-Kyu ParkHong-Joon ShinJung-Hwan LimYong-Soo KwonYu-Il KimSung-Chul LimYoung-Chul KimYoo-Duk Choi

Published in: Thoracic cancer (2018)

Re-biopsy in advanced NSCLC is feasible in real world clinical practice, particularly in younger patients and those who achieved a previous response to EGFR-TKIs.

Keyphrases

small cell lung cancer
clinical practice
epidermal growth factor receptor
end stage renal disease
tyrosine kinase
ejection fraction
newly diagnosed
ultrasound guided
fine needle aspiration